Overall, our data provide further support for a role of HGF and MCP-2 as candidate biomarkers of response to ICI in advanced melanoma, while proposing an additive negative effect of these two cytokines, together with IL-6, on response rates. The gene discussed is IL6; the disease is melanoma.